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Abstract
The objective of this study was to test the hypothesis that 4 weeks of lithium administration would
be associated with changes in brain gray and white matter volumes in healthy individuals. Thirteen
right-handed healthy volunteers (6 females, mean age = 25.9 ± 10.0 y) were studied. 3D SPGR MRIs
(TR = 25ms, TE = 5ms, slice-thickness = 1.5mm) were acquired using a 1.5 T GE Signa Imaging
System, at baseline and after 4 weeks of lithium administration at therapeutically relevant doses.
Optimized voxel based morphometry (VBM) analyses were conducted. Left and right dorsolateral
prefrontal cortex and left anterior cingulate gray matter volumes increased significantly following
lithium administration. Total white matter volume was increased, whereas total brain volume and
total gray matter volume were not significantly changed following 4 weeks of lithium. Lithium
treatment resulted in prefrontal regional gray matter volume increases in healthy volunteers, as well
as increases in total white matter volume. Whether these changes are mediated by neurotrophic/
neuroprotective or osmotic effects remains unknown.
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Introduction
Lithium is the most widely used mood stabilizer for the treatment of bipolar disorder. It affects
multiple cellular signaling pathways in the brain [1] and has neurotrophic and neuroprotective
effects [2]. Studies utilizing anatomical region-of-interest [3,4] and cortical pattern matching
[5] methods, as well as neurochemical imaging [6], demonstrated detectable brain changes
related to lithium treatment in bipolar patients. Specifically, both cross-sectional [4,5] and
longitudinal prospective [3] studies demonstrated increased total gray matter volumes in
bipolar patients treated with lithium compared to both untreated patients and age- and sex-
matched healthy comparisons. Furthermore, proton magnetic resonance spectroscopy studies
demonstrated increased levels of total brain N-acetyl-aspartate, a putative marker of neuronal
viability, myelin formation and maintenance, after 4 weeks of lithium in bipolar patients and
healthy volunteers [6]. The effect of lithium on the healthy human brain is an intriguing finding,
and it may help clarify the mechanisms by which lithium exerts its effects in bipolar patients.
We previously measured the metabolite levels for N-acetyl-aspartate, glycerophosphocholine
plus phosphocholine and myo-inositol in the left and right dorsolateral prefrontal cortices
(DLPFC) in a sample of healthy individuals before and after 4 weeks of lithium administration,
and found no significant changes [7]. The objective of this study was to complement these
neurochemical results with neuroanatomical measurements, using voxel-based morphometry
(VBM), a technique that aims to identify differences in the local composition of brain tissue,
after discounting large scale differences in gross anatomy and position [8] and BRAINS2 [9].
We hypothesized that chronic lithium administration would be associated with changes in brain




This study protocol was approved by the University of Pittsburgh Biomedical IRB. All subjects
gave their informed consent for participation in the study. The sample consisted of 13 right-
handed healthy volunteers (6 females, 7 males; mean age = 25.9 ± 10.0 y, range 18-52 y). They
were evaluated with the Structured Clinical Interview for DSM-IV non-patient version. The
subjects had no current major medical illnesses, no past or current DSM-IV axis I disorders,
or first-degree relative with any psychiatric disorders. MRI scans were done at baseline and
after 4 weeks of lithium given at doses (600-1500 mg/day) that produced a mean blood level
of 0.6 mEq/l throughout the 4 weeks, and 0.83 mEq/l at the end of the 4th week (mean blood
lithium levels for weeks 1, 2 and 3 were 0.34 mEq/l, 0.53 mEq/l, 0.67 mEq/l, respectively).
We started lithium at 300 mg/day, increased to 600 mg/day on the second day and maintained
the dose at 600 mg/day for the first week. The 12-h lithium blood levels were obtained at the
end of the first week and weekly thereafter, and doses were adjusted accordingly to maintain
a minimum blood level of 0.6 mEq/l through the following 3 weeks.
Image Acquisition
MRIs were performed on a 1.5T GE Signa Imaging System running version Signa 5.4.3
software (General Electric Medical Systems, Milwaukee, WI). We used 3D gradient echo
imaging (Spoiled Gradient Recalled Acquisition, SPGR), performed in the coronal plane (TR
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= 25 ms, TE = 5 ms; flip angle = 40°; FOV = 24 cm; slice thickness = 1.5 mm; voxel size =
1× 1 × 1.5 mm; NEX = 1; matrix size = 256 × 192), to obtain 124 images covering the entire
brain.
Data Analysis
Image analysis was performed using a Linux (Fedora Core 4) workstation with MATLAB 7.1
(MathWorks, Natick, MA). Optimized VBM analyses were conducted with Statistical
Parametrical Mapping (SPM2, Wellcome Department of Cognitive Neurology, University
College London, UK). The images were preprocessed following the optimized VBM protocol
[8]. The T1-weighted images were realigned and segmented into gray, white and CSF
compartments, using the customized template from all T1 MRI scans by an optimized VBM
script (http://dbm.neuro.uni-jena.de/vbm.html). The segmented images were modulated and
smoothed with a 12-mm full-width half-maximum Gaussian kernel. Contrasts were performed
to identify changes in gray and white matter volumes from baseline to lithium conditions using
two-sided paired t-tests. We defined the cingulate, dorsolateral prefrontal cortex (DLPFC),
amygdala and hippocampus bilaterally as regions of interest (ROI). We used small volume
correction for ROI analysis. Significant results are reported at p < 0.05 corrected for multiple
comparisons. All results are reported as Talairach coordinates using Talairach Daemon
(ric.uthscsa.edu/projects/talairachdaemon.html). Talairach coordinates were obtained by
applying Brett’s transformation
(www.mrc=cbu.cam.ac.uk/Imaging/Common/mnispace.shtml) to the Montreal Neurological
Institute (MNI) coordinates output by SPM2.
Total brain volume and total gray and white matter volumes were manually traced by one rater
using BRAINS2 software, developed at the University of Iowa Hospitals and Clinics [9].
We used paired samples t test to calculate the change in total brain, total gray matter and white
matter volumes following 4 weeks of lithium. Nonparametric correlations were used to
calculate the correlation between mean lithium blood levels and the observed changes in total
brain, total gray matter and white matter volumes and the significant ROIs.
Results
The mean lithium blood level at the end of four weeks was 0.83 ± 2.0 mEq/l, with a mean
lithium dosage of 1281 ± 218 mg/day. In the paired samples t test, we found that total white
matter volumes were increased by 2%, whereas total brain volume and total gray matter volume
remained unchanged following 4 weeks of lithium administration (Tables 1 and 2).
Left DLPFC (Brodmann’s area 46) gray matter volume was significantly increased following
lithium administration (Talairach coordinates: x = -36, y = 32, z = 20, Z = 3.57, k = 349,
pcorrected = 0.040) (Figure 1). Right DLPFC (Talairach coordinates: x = 54, y = 30, z = 23, Z
= 4.02, k = 1212, pcorrected = 0.007) and left anterior cingulate (ACC - Brodmann 10) gray
matter volumes also increased significantly following lithium administration (Talairach
coordinates: x = -8, y = 46, z = 6; borderline between ACC and medial frontal gyrus, Z = 3.63,
k = 479, pcorrected = 0.038) (Figure 1). None of the ROIs showed statistically significant change
in white matter content, and none of the other ROIs showed statistically significant change in
gray matter content with lithium administration.
Mean lithium blood levels were not significantly correlated with left and right DLPFC and left
ACC gray matter changes, or with the changes observed in the brain and total white and gray
matter volumes (nonparametric correlations, all p>0.05).
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VBM analyses revealed significant increases the left and right DLPFC and left ACC gray
matter volumes in healthy individuals after 4 weeks of lithium administration. Also, total white
matter volumes were increased by 2%, whereas total brain volume and total gray matter volume
remained unchanged.
DLPFC and ACC are subdivisions of the prefrontal cortex, which is a primary brain region of
interest in the pathophysiology of bipolar disorder. Both regions have been shown to be affected
in bipolar disorder. Left ACC gray matter volume is reduced in adult [10] and juvenile [11]
bipolar patients. Research employing a statistical parametric mapping approach also revealed
reduced gray matter density in the fronto-limbic cortex, particularly in the cingulate [12,13],
and in Bearden and colleagues’ study [5] greatest differences in gray matter density were found
in the bilateral cingulate and paralimbic cortices in lithium-treated bipolar patients (n=20)
compared to those not taking lithium (n=8) and healthy controls (n=28). The DLPFC is an
understudied region in bipolar disorder, with one study [14] showing significantly smaller gray
matter volumes in the left middle and superior, and the right middle and inferior prefrontal
regions in 17 bipolar patients hospitalized for a manic episode and receiving various
psychotropic medications, and another study demonstrating decreased gray matter volume in
the left DLPFC in pediatric bipolar patients [15]. Bearden and colleagues [5] also noted greater
gray matter density in the left DLPFC in lithium-treated bipolar patients compared to healthy
controls. Taken together, the detected gray matter increases in these regions may be associated
with the therapeutic effects of lithium, although we should note that our subjects were all
healthy controls.
Apart from the regional changes in the ACC and DLPFC, total brain white matter volumes
were increased after 4 weeks of lithium administration. One longitudinal [3] study showed an
average 3% increase in total brain gray matter in eight out of ten bipolar patients treated with
4 weeks of lithium, while there were no changes in the white matter, or the regional cerebral
water content (measured by magnetic resonance spectroscopy). Another study, although cross-
sectional, showed that bipolar patients treated with lithium had greater total gray matter
volumes than untreated bipolar patients and healthy controls, while there were no significant
differences in total white matter volumes across three groups [4]. Also in Bearden and
colleagues’ study [5], no white matter changes were detected. It is hard to explain why we
found total white matter changes in healthy subjects who took lithium for four weeks, as most
other studies failed to identify any effects in white matter. One explanation is that lithium may
have different generalized effects in healthy and diseased brains. This global white matter
increase is also of interest considering recent evidence for white matter pathology as an early
marker for bipolar disorder [16] and lithium’s effect of causing formation of multiple axons in
rat hippocampus neurons through inhibition of glycogen synthase kinase-3β [17].
These gray and white matter findings may reflect neuroprotective and neurotrophic effects of
lithium, as suggested possibly by neuropil increase [2,3], as lithium also enhances neurogenesis
and prevents injury to nerve cells via various insults [18]. Recently, Yucel and colleagues
[19] examined the effects of lithium on hippocampal volume in a medication-naïve sample of
bipolar patients, treated with 1-8 weeks of lithium, and showed that there was a bilateral
increase in total hippocampus and hippocampal head volumes in patients treated with lithium,
compared to unmedicated patients.
The osmotic effects of lithium, which may lead to neuron swelling, may provide an alternative
explanation for the increased brain volumes following lithium administration. Phatak and
colleagues [20] demonstrated that chronic (5 weeks, at 0.82 mEq/L blood lithium
concentrations) lithium administration resulted in 3.1% elevation of tissue water content in
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frontal cortex and hippocampus and 0.8% elevation of tissue water content in cerebellum in
rat brains [20]. This effect was statistically significant only in frontal gray matter (white matter
was not sampled), and was not observed in rats treated with 11 days of lithium. Although the
global white matter volume increase we observed may be due to an osmotic effect, we found
significant gray matter effects only in certain prefrontal ROIs (cingulate and DLPFC), but not
globally or in other ROIs (i.e. amygdala and hippocampus), a finding that makes the osmotic
explanation unlikely.
One of the limitations of our study is that the lithium levels obtained were in the low range
(∼0.6 mEq/l) throughout 4 weeks, although at the end of 4th week the mean lithium blood level
was 0.83 mEq/l. Also, the small number of subjects involved in the study with the lack of a
control group (untreated or with administration of placebo or another drug), and the absence
of data on the test re-test reliability of the MRI machine are other potential limitations of this
study. Although 7-17 days of lithium treatment does not seem to produce any significant
changes in either T1 or T2 relaxation times in rat brains [21], the presence of lithium in the
healthy human brain altering the T1 properties of cerebrospinal fluid, gray and white matter,
so that one may be classified as the other in the repeat scan, is yet another point that must be
kept in mind when interpreting our results.
In conclusion, 4 weeks of lithium administration led to significant increases in the left and right
DLPFC and left ACC gray matter volumes and total white matter volume in healthy individuals.
Whether these effects are due to increased neuropil or osmotic effects of lithium needs to be
determined.
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Regions of increased gray matter after 4 weeks of lithium administration are shown. The red
areas show the significant increases in gray matter volumes in the left and right DLPFC and
left ACC in 13 healthy volunteers after 4 weeks of lithium administration at therapeutically
relevant doses. Right to left (and from top to bottom): left medial, right medial, posterior,
anterior, right lateral, left lateral, ventral and dorsal views of the brain with the significant
regions marked in red color.
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